These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 26696909)

  • 1. Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy.
    Zorumski CF; Nagele P; Mennerick S; Conway CR
    Front Psychiatry; 2015; 6():172. PubMed ID: 26696909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
    Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
    J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
    Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
    Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.
    Iadarola ND; Niciu MJ; Richards EM; Vande Voort JL; Ballard ED; Lundin NB; Nugent AC; Machado-Vieira R; Zarate CA
    Ther Adv Chronic Dis; 2015 May; 6(3):97-114. PubMed ID: 25954495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents.
    Kalmoe MC; Janski AM; Zorumski CF; Nagele P; Palanca BJ; Conway CR
    J Neurol Sci; 2020 May; 412():116778. PubMed ID: 32240970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.
    du Jardin KG; Müller HK; Elfving B; Dale E; Wegener G; Sanchez C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():27-38. PubMed ID: 27262695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of ketamine action as an antidepressant.
    Zanos P; Gould TD
    Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
    Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
    Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrous Oxide: an emerging novel treatment for treatment-resistant depression.
    Quach DF; de Leon VC; Conway CR
    J Neurol Sci; 2022 Mar; 434():120092. PubMed ID: 34953347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine's antidepressant action: beyond NMDA receptor inhibition.
    Hashimoto K
    Expert Opin Ther Targets; 2016 Nov; 20(11):1389-1392. PubMed ID: 27646666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine's fast-acting antidepressant mechanisms.
    Marcatili M; Sala C; Dakanalis A; Colmegna F; D'Agostino A; Gambini O; Dell'Osso B; Benatti B; Conti L; Clerici M
    Ther Adv Psychopharmacol; 2020; 10():2045125320968331. PubMed ID: 33224469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of NMDA receptors in the treatment of major depression.
    Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
    Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketamine: NMDA Receptors and Beyond.
    Zorumski CF; Izumi Y; Mennerick S
    J Neurosci; 2016 Nov; 36(44):11158-11164. PubMed ID: 27807158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants.
    Browne CA; Lucki I
    Front Pharmacol; 2013 Dec; 4():161. PubMed ID: 24409146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
    Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
    Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.
    Aleksandrova LR; Phillips AG; Wang YT
    J Psychiatry Neurosci; 2017 Jun; 42(4):222-229. PubMed ID: 28234212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant.
    Xu S; Yao X; Li B; Cui R; Zhu C; Wang Y; Yang W
    Front Pharmacol; 2021; 12():740996. PubMed ID: 35872836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
    Miller OH; Moran JT; Hall BJ
    Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.